vs
朗美通（LITE）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
朗美通的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.8倍（$665.5M vs $373.9M），朗美通净利率更高（11.8% vs 7.3%，领先4.4%），朗美通同比增速更快（65.5% vs 20.9%），朗美通自由现金流更多（$43.1M vs $8.3M），过去两年朗美通的营收复合增速更高（34.8% vs 19.2%）
朗美通控股（Lumentum Holdings Inc.）是全球知名光电产品供应商，前身为美国捷迪讯（JDSU）旗下光电器件及激光业务板块，2015年8月随捷迪讯分拆独立运营，总部位于美国加利福尼亚州米尔皮塔斯，主营光通信网络设备、激光器、定制光学解决方案等多元产品。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
LITE vs PAHC — 直观对比
营收规模更大
LITE
是对方的1.8倍
$373.9M
营收增速更快
LITE
高出44.6%
20.9%
净利率更高
LITE
高出4.4%
7.3%
自由现金流更多
LITE
多$34.8M
$8.3M
两年增速更快
LITE
近两年复合增速
19.2%
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $665.5M | $373.9M |
| 净利润 | $78.2M | $27.5M |
| 毛利率 | 36.1% | 35.5% |
| 营业利润率 | 9.7% | 13.5% |
| 净利率 | 11.8% | 7.3% |
| 营收同比 | 65.5% | 20.9% |
| 净利润同比 | 228.4% | 762.1% |
| 每股收益（稀释后） | $0.89 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LITEPAHC
| Q4 25 | $665.5M | $373.9M | ||
| Q3 25 | $533.8M | $363.9M | ||
| Q2 25 | $480.7M | $378.7M | ||
| Q1 25 | $425.2M | $347.8M | ||
| Q4 24 | $402.2M | $309.3M | ||
| Q3 24 | $336.9M | $260.4M | ||
| Q2 24 | $308.3M | $273.2M | ||
| Q1 24 | $366.5M | $263.2M |
净利润LITEPAHC
| Q4 25 | $78.2M | $27.5M | ||
| Q3 25 | $4.2M | $26.5M | ||
| Q2 25 | $213.3M | $17.2M | ||
| Q1 25 | $-44.1M | $20.9M | ||
| Q4 24 | $-60.9M | $3.2M | ||
| Q3 24 | $-82.4M | $7.0M | ||
| Q2 24 | $-252.5M | $752.0K | ||
| Q1 24 | $-127.0M | $8.4M |
毛利率LITEPAHC
| Q4 25 | 36.1% | 35.5% | ||
| Q3 25 | 34.0% | 32.9% | ||
| Q2 25 | 33.3% | 29.0% | ||
| Q1 25 | 28.8% | 30.1% | ||
| Q4 24 | 24.8% | 32.9% | ||
| Q3 24 | 23.1% | 32.1% | ||
| Q2 24 | 16.6% | 31.9% | ||
| Q1 24 | 16.2% | 30.2% |
营业利润率LITEPAHC
| Q4 25 | 9.7% | 13.5% | ||
| Q3 25 | 1.3% | 14.1% | ||
| Q2 25 | -1.7% | 8.9% | ||
| Q1 25 | -8.9% | 9.6% | ||
| Q4 24 | -12.8% | 8.3% | ||
| Q3 24 | -24.5% | 6.8% | ||
| Q2 24 | -43.3% | 6.7% | ||
| Q1 24 | -31.3% | 7.6% |
净利率LITEPAHC
| Q4 25 | 11.8% | 7.3% | ||
| Q3 25 | 0.8% | 7.3% | ||
| Q2 25 | 44.4% | 4.5% | ||
| Q1 25 | -10.4% | 6.0% | ||
| Q4 24 | -15.1% | 1.0% | ||
| Q3 24 | -24.5% | 2.7% | ||
| Q2 24 | -81.9% | 0.3% | ||
| Q1 24 | -34.7% | 3.2% |
每股收益（稀释后）LITEPAHC
| Q4 25 | $0.89 | $0.67 | ||
| Q3 25 | $0.05 | $0.65 | ||
| Q2 25 | $3.10 | $0.43 | ||
| Q1 25 | $-0.64 | $0.51 | ||
| Q4 24 | $-0.88 | $0.08 | ||
| Q3 24 | $-1.21 | $0.17 | ||
| Q2 24 | $-3.75 | $0.02 | ||
| Q1 24 | $-1.88 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $74.5M |
| 总债务越低越好 | — | $624.2M |
| 股东权益账面价值 | $846.6M | $332.4M |
| 总资产 | $4.8B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资LITEPAHC
| Q4 25 | $1.2B | $74.5M | ||
| Q3 25 | $1.1B | $85.3M | ||
| Q2 25 | $877.1M | $77.0M | ||
| Q1 25 | $866.7M | $70.4M | ||
| Q4 24 | $896.7M | $67.1M | ||
| Q3 24 | $916.1M | $89.8M | ||
| Q2 24 | $887.0M | $114.6M | ||
| Q1 24 | $870.9M | $98.7M |
总债务LITEPAHC
| Q4 25 | — | $624.2M | ||
| Q3 25 | — | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | — | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
股东权益LITEPAHC
| Q4 25 | $846.6M | $332.4M | ||
| Q3 25 | $780.8M | $311.7M | ||
| Q2 25 | $1.1B | $285.7M | ||
| Q1 25 | $879.5M | $266.0M | ||
| Q4 24 | $872.3M | $246.8M | ||
| Q3 24 | $895.9M | $258.5M | ||
| Q2 24 | $957.3M | $256.6M | ||
| Q1 24 | $1.2B | $270.1M |
总资产LITEPAHC
| Q4 25 | $4.8B | $1.4B | ||
| Q3 25 | $4.6B | $1.4B | ||
| Q2 25 | $4.2B | $1.4B | ||
| Q1 25 | $4.0B | $1.3B | ||
| Q4 24 | $4.0B | $1.3B | ||
| Q3 24 | $4.0B | $966.3M | ||
| Q2 24 | $3.9B | $982.2M | ||
| Q1 24 | $4.2B | $979.0M |
负债/权益比LITEPAHC
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.7M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $43.1M | $8.3M |
| 自由现金流率自由现金流/营收 | 6.5% | 2.2% |
| 资本支出强度资本支出/营收 | 12.6% | 3.0% |
| 现金转化率经营现金流/净利润 | 1.62× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $-29.5M | $47.3M |
8季度趋势，按日历期对齐
经营现金流LITEPAHC
| Q4 25 | $126.7M | $19.4M | ||
| Q3 25 | $57.9M | $9.3M | ||
| Q2 25 | $64.0M | $21.3M | ||
| Q1 25 | $-1.6M | $43.2M | ||
| Q4 24 | $24.3M | $3.1M | ||
| Q3 24 | $39.6M | $12.6M | ||
| Q2 24 | $35.5M | $28.4M | ||
| Q1 24 | $-7.0M | $11.4M |
自由现金流LITEPAHC
| Q4 25 | $43.1M | $8.3M | ||
| Q3 25 | $-18.3M | $-4.5M | ||
| Q2 25 | $10.1M | $8.1M | ||
| Q1 25 | $-64.4M | $35.4M | ||
| Q4 24 | $-15.9M | $-4.7M | ||
| Q3 24 | $-34.5M | $3.0M | ||
| Q2 24 | $10.9M | $15.4M | ||
| Q1 24 | $-26.6M | $1.7M |
自由现金流率LITEPAHC
| Q4 25 | 6.5% | 2.2% | ||
| Q3 25 | -3.4% | -1.2% | ||
| Q2 25 | 2.1% | 2.1% | ||
| Q1 25 | -15.1% | 10.2% | ||
| Q4 24 | -4.0% | -1.5% | ||
| Q3 24 | -10.2% | 1.2% | ||
| Q2 24 | 3.5% | 5.6% | ||
| Q1 24 | -7.3% | 0.6% |
资本支出强度LITEPAHC
| Q4 25 | 12.6% | 3.0% | ||
| Q3 25 | 14.3% | 3.8% | ||
| Q2 25 | 11.2% | 3.5% | ||
| Q1 25 | 14.8% | 2.2% | ||
| Q4 24 | 10.0% | 2.5% | ||
| Q3 24 | 22.0% | 3.7% | ||
| Q2 24 | 8.0% | 4.8% | ||
| Q1 24 | 5.3% | 3.7% |
现金转化率LITEPAHC
| Q4 25 | 1.62× | 0.70× | ||
| Q3 25 | 13.79× | 0.35× | ||
| Q2 25 | 0.30× | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LITE
| Components | $443.7M | 67% |
| Systems | $221.8M | 33% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
